Disclosure: The authors declared no conflict of interest. Funding agencies: This work was supported by RO1DK068261, the Nutrition Obesity Research Center (P30DK56336), the Diabetes Research and Training Grant (P60DK079626).
Effects of risperidone on energy balance in female C57BL/6J mice
Article first published online: 29 MAY 2013
Copyright © 2013 The Obesity Society
Volume 21, Issue 9, pages 1850–1857, September 2013
How to Cite
Li, X., Johnson, M. S., Smith, D. L., Li, Y., Kesterson, R. A., Allison, D. B. and Nagy, T. R. (2013), Effects of risperidone on energy balance in female C57BL/6J mice. Obesity, 21: 1850–1857. doi: 10.1002/oby.20350
- Issue published online: 23 SEP 2013
- Article first published online: 29 MAY 2013
- Accepted manuscript online: 14 FEB 2013 07:19AM EST
- Manuscript Accepted: 12 DEC 2012
- Manuscript Received: 19 APR 2012
- The Nutrition Obesity Research Center. Grant Numbers: RO1DK068261, P30DK56336
- The Diabetes Research and Training Grant. Grant Number: P60DK079626
To investigate the effect of risperidone on energy expenditure and weight gain in female C57BL/6J mice.
Design and Methods
Body weight and composition, food intake, energy expenditure, and activity were determined weekly. mRNA expression of uncoupling protein 1 in brown adipose tissue, orexin, and brain-derived neurotrophic factor in the hypothalamus were quantified using real-time PCR.
Risperidone tended to induce a greater body weight gain (P = 0.052) and significantly higher food intake (P = 0.038) relative to the placebo-treated group. Risperidone-treated mice had a higher resting energy expenditure (P = 0.001) and total energy expenditure (TEE) (P = 0.005) than the placebo group. There were no effects of treatment, time, and treatment by time on non-resting (or activity-related) energy expenditure between groups. Risperidone-treated mice showed a significantly lesser locomotor activity than placebo-treated mice over 3 weeks (P < 0.001). Risperidone induced a higher UCP1 mRNA (P = 0.003) and a lower orexin mRNA (P = 0.001) than placebo.
Risperidone-induced weight gain is associated with hyperphagia and a reduction in locomotor activity in C57BL/6J mice. Additionally, higher total and resting energy expenditure were accompanied by higher levels of UCP1 mRNA in BAT. The increased TEE could not offset the total intake of energy through risperidone-induced hyperphagia, therefore resulting in weight gain in female C57BL/6J mice.